cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Novavax Inc
223 own
150 watching
Current Price
$5.5
$-0.06
(-1.08%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
663.58M
52-Week High
52-Week High
18.55000
52-Week Low
52-Week Low
5.30000
Average Volume
Average Volume
5.61M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization663.58M
icon52-Week High18.55000
icon52-Week Low5.30000
iconAverage Volume5.61M
iconDividend Yield--
iconP/E Ratio--
What does the Novavax Inc do?
Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Read More
How much money does Novavax Inc make?
News & Events about Novavax Inc.
CNBC: Business
5 months ago
The FDA's decision is a win for vaccine makers Pfizer, Moderna and Novavax, which have all been developing versions of their Covid shots to target XBB.1.5...
PR Newswire
5 months ago
Thinking about buying stock in Applied UV, CBAK Energy Technology, Novavax, C3.ai, or DBV Technologies? Thinking about buying stock in Applied UV, CBAK Energy Technology, Novavax, C3.ai, or DBV Technologies? PR Newswire NEW YORK, June 16, 2023 NEW YORK, June 16, 2023 /PRNewswire...
PR Newswire
5 months ago
Novavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023 Novavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023 PR Newswire GAITHERSBURG, Md., June 15, 2023 GAITHERSBURG, Md., June 15, 2023 /PRNewswire/ --Novavax, Inc. (Nasdaq: NVAX), a...
Stock Options Channel
7 months ago
Investors in Novavax, Inc. (NVAX) saw new options become available today, for the June 23rd expiration...
PR Newswire
7 months ago
Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023 Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023 PR Newswire GAITHERSBURG, Md., May 2, 2023...
Frequently Asked Questions
Frequently Asked Questions
What is Novavax Inc share price today?
plus_minus_icon
Can Indians buy Novavax Inc shares?
plus_minus_icon
How can I buy Novavax Inc shares from India?
plus_minus_icon
Can Fractional shares of Novavax Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Novavax Inc stocks?
plus_minus_icon
What is today’s traded volume of Novavax Inc?
plus_minus_icon
What is today’s market capitalisation of Novavax Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Novavax Inc?
plus_minus_icon
What percentage is Novavax Inc down from its 52-Week High?
plus_minus_icon
What percentage is Novavax Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.5
$-0.06
(-1.08%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.50
$0.00 (0.40 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.05
$0.15 (7.89 %)
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
$19.16
$0.38 (2.02 %)
TG Therapeutics Inc
TG Therapeutics Inc
$12.80
$0.31 (2.48 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.50
$0.00 (0.40 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.05
$0.15 (7.89 %)
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
$19.16
$0.38 (2.02 %)
TG Therapeutics Inc
TG Therapeutics Inc
$12.80
$0.31 (2.48 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00